Understanding the links between drug delivery route and in vitro test methods

whitePaper | April 8, 2020

EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.

whitePaper | March 14, 2022

Over the past several years, biologics have gained significant traction in the pharmaceutical industry, representing more than $150 billion in global sales in 2013. By 2020 they are predicted to generate $290 billion in revenue and comprise 27 percent of the pharmaceutical market.i

whitePaper | February 16, 2023

Monoclonal antibody drugs (mAbs) make up more than 50 percent of the biologics on the market today, as well as a significant number of new drugs in the development pipeline. The value and impact of these therapies has been dramatic.

whitePaper | January 10, 2023

The ideal care model for complex patients is a model in which the entire health care team is made up of experts in the specific disease state being treated. Integrated health care systems and major academic medical centers provide this level of expertise and coordination.

whitePaper | October 13, 2022

In our previous edition of the Clinical Trials Roundup1, we explored the acute disruptions that the COVID-19 pandemic brought to the clinical trials landscape in 2020.

whitePaper | February 28, 2022

Starting in Week 9 of 2020, prescription volume and claims data entered a period of intense volatility, followed by a steady state